Opinion on Pharmaceuticals in Switzerland

Published within

« | 1 | 2 | 3 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Novartis: strengthening vaccines presence in the lucrative Chinese market

Novartis has completed the acquisition of an 85% stake in the Chinese vaccines company Zhejiang Tianyuan Bio-Pharmaceuticals. Faced with limited growth opportunities in the Western markets, all major vaccines players are expanding activities into growth markets due to the high incidence of vaccine-preventable diseases and increasing public and private healthcare spending.

Published By Datamonitor
24 Mar 2011
CommentWire
CommentWire

Roche: Q3 results highlight dependence on big three MAbs

Roche's Q3 2010 and year-to-date sales are down on the year prior, due primarily to a large decline in demand for the antiviral Tamiflu, although the company's impressive MAb trio of Avastin, Herceptin and MabThera continue to provide strong sales. However, Roche is looking to lower its dependency on these blockbusters, having inked a deal with InterMune for hepatitis C small molecule danoprevir.

Published By Datamonitor
14 Oct 2010
CommentWire
CommentWire

Genentech: rejects Roche bid

Genentech has declined the $43.7 billion takeover bid made by Swiss pharmaceutical giant Roche, on the grounds that the offer undervalues the benefits that full-ownership of the US biotech would provide. Genentech's unsurprising decision leaves the door open to further negotiations, with a deal expected to be finalized within the next few months.

Published By Datamonitor
14 Aug 2008
CommentWire
CommentWire

Roche: Piramed acquisition strengthens its oncology and I&I portfolio

Roche has agreed to acquire Piramed for $160m plus a milestone payment of $15m, due upon the start of Phase II clinical trials for the company's oncology program. Piramed's oncology and immunology and inflammation programs will add to Roche's already strong portfolio in these therapy areas and the move is in line with Roche's strategy of pursuing these two fastest growing therapeutic segments.

Published By Datamonitor
15 Apr 2008
Expert View
Expert View

Novartis eyes Alcon to drive diversification strategy

Novartis has agreed to acquire a controlling stake in ophthalmology specialist Alcon for around $39 billion, revealing a clear intention to drive diversification from its core prescription pharmaceutical business. Although Alcon will not come cheap, the acquisition represents a positive, long-term strategy by Novartis which faces intensifying generic competition over the next five years.

Published By Datamonitor
08 Apr 2008
CommentWire
CommentWire

Roche: Xelox to challenge FOLFOX in colorectal cancer

A phase III trial of Roche's Xelox regimen in colorectal cancer has proven successful, with the study finding Xelox to be as effective as FOLFOX, the current standard first-line treatment for metastatic colorectal tumors. However, numerous challenges still face Roche if the regimen is to make a significant impact upon the colorectal tumor market.

Published By Datamonitor
02 Aug 2006
CommentWire
CommentWire

Novartis: continuing its infectious diseases drive

Novartis has bolstered its infectious disease pipeline with two acquisitions in as many days. The Swiss firm has signed a global agreement with US-based Human Genome Sciences for hepatitis C drug candidate Albuferon and made an offer for UK-based anti-infectives developer NeuTec Pharma.

Published By Datamonitor
07 Jun 2006
CommentWire
CommentWire

Novartis: building its antiviral arsenal

Novartis has announced a $507 million licensing deal with Human Genome Sciences for Albuferon, giving Novartis rights to co-promote the hepatitis C drug candidate in the US, with exclusive marketing and promotion rights outside the US. This is the Swiss firm's latest step in its strategy to build a versatile hepatitis C portfolio and become a leading player in this high-growth market.

Published By Datamonitor
06 Jun 2006
CommentWire
CommentWire

Speedel/Novartis: hypertension hype or hope?

Speedel and Novartis' Rasilez, the first, orally available direct renin inhibitor, has demonstrated in a phase III trial that it is a safe addition to the current antihypertensive armamentarium. The results clearly show that the novel agent is a viable treatment option, but whether this clinical success can translate into commercial potential remains to be seen, as further hurdles await.

Published By Datamonitor
18 May 2006
CommentWire
CommentWire

Novartis: Sandoz drives profit surge

Driven by strong gains made by its generics business and double-digit growth from key drugs, Novartis has posted impressive Q1 sales of $8.3 billion and a 31% rise in operating profit. Bolstered by a strong pipeline and the acquisition of Chiron, it could now go on to achieve record growth in 2006.

Published By Datamonitor
26 Apr 2006

« | 1 | 2 | 3 | » »|

No help is available.